Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease.
With our lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform to create a robust pipeline including: tab-cel® (tabelecleucel) in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD); ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies.
Improving patients’ lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.
Working at Atara
People at Atara are high integrity, collaborative, roll-up-your-sleeves types who are deeply committed to putting patients first and advancing medical care with demonstrated urgency. With many accomplished people at Atara, we share humility, flexibility, respect, teamwork, good judgment and being practical in our approach to advance our therapies. We each enjoy in the journey of advancing cutting edge programs, while responsibly teaching and learning together along the way.
Location: United States, California, South San Francisco
Employees: 501-1000
Total raised: $90.5M
Founded date: 2012
Investors 4
Date | Name | Website |
- | Domain Ass... | domainvc.c... |
- | Kleiner Pe... | kleinerper... |
- | EcoR1 Capi... | ecor1cap.c... |
- | DAG Ventur... | dagventure... |
Funding Rounds 2
Date | Series | Amount | Investors |
10.01.2014 | Series B | $52M | - |
17.12.2013 | Series B | $38.5M | - |
Mentions in press and media 19
Date | Title | Description | Source |
23.02.2024 | Pierre Fabre Laboratories, committed to combating rare pedia... | 70% of rare genetic diseases start in childhood[1,2] CASTRES, France, Feb. 23, 2024 /PRNewswire/ -- ... | en.prnasia... |
27.01.2022 | Fujifilm expands in US after $100M deal for Atara's man... | Atara Biotherapeutics has worked on advancing its allogeneic T-cell therapy platform for... | endpts.com... |
09.04.2021 | John Robinson recruits a small band of Array vets to kick... | John Robinson Biotech is a small world — and all the more so in a tight-knit community like Boul... | endpts.com... |
01.03.2021 | Atara Biotherapeutics Announces Fourth Quarter and Full Year... | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 1, 2021-- Atara Biotherapeutics, Inc. (Nasdaq: ATR... | oaoa.com/n... |
04.12.2018 | Atara’s EBV-CTLs show responses in hard-to-treat transplant ... | What makes PTLD especially difficult to treat when it reaches the CNS is that one of the standard PT... | medcitynew... |
29.06.2016 | The biotech IPO feast flags as investors lose their appeti... | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. B... | endpts.com... |
10.01.2014 | Atara Biotherapeutics Raises $52M | Thousand Oaks-based Atara Biotherapeutics announced this morning that it is in a second close of its... | socaltech.... |
10.01.2014 | Atara Biotherapeutics Holds $13.5M Second Close of Series B ... | Atara Biotherapeutics, Inc., a Thousand Oaks, CA-based drug development company with a focus on inno... | finsmes.co... |
10.01.2014 | Atara Biotherapeutics Inks Second Closing of $52M Series B | BRISBANE, CA, Drug development company with a focus on innovative therapies for patients with debi... | vcnewsdail... |
17.12.2013 | Atara Biotherapeutics Inks $38.5M in Series B | BRISBANE, CA, Drug development company with a focus on innovative therapies for patients with debi... | vcnewsdail... |
Show more